15:01 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Autifony begins Phase Ib of AUT00206 in schizophrenia

Autifony Therapeutics Ltd. (Stevenage, U.K.) began a double-blind, placebo-controlled, U.K. Phase Ib trial of twice-daily 800 mg oral AUT00206 for 4 weeks as adjunctive therapy in about 24 recently diagnosed schizophrenic patients. The trial is...
21:32 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

AUT00206: Additional Ph Ia data

Data from 32 evaluable healthy volunteers in a double-blind, placebo-controlled, U.K. Phase Ia trial showed that oral AUT00206 significantly reduced Mismatch Negativity (MMN) latency at 8 hours post-dose on day 1. According to the company,...
01:21 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

AUT00206: Ph Ib started

Autifony began a double-blind, 4-way crossover, U.K. Phase Ib trial of oral AUT00206 in about 16 healthy male volunteers. Subjects will receive 800 or 2,000 mg AUT00206 or placebo during a ketamine challenge or placebo...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

AUT00206: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in over 60 healthy volunteers showed that single ascending doses and once-daily doses of oral AUT00206 for up to 28 days given in fed and fasted states were...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

AUT00206: Phase I started

Autifony began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate oral AUT00206 in healthy men. In the first part, up to 24 volunteers will receive up to 5 single doses either after fasting...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

AUT00063: Phase I started

Autifony began a placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending-doses of oral AUT00063 in about 60 healthy volunteers. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) spun out Autifony in 2011 to develop...
07:00 , Jun 17, 2013 |  BioCentury  |  Emerging Company Profile

Autifony: Sense and sensitivity

Autifony Therapeutics Ltd. is developing compounds for hearing loss and tinnitus that modulate potassium channel Kv3 , a target on inhibitory receptors of the CNS that may affect central auditory processing of speech and other...